JP7065862B2 - 癌の再発および進行のモニタリング - Google Patents
癌の再発および進行のモニタリング Download PDFInfo
- Publication number
- JP7065862B2 JP7065862B2 JP2019538737A JP2019538737A JP7065862B2 JP 7065862 B2 JP7065862 B2 JP 7065862B2 JP 2019538737 A JP2019538737 A JP 2019538737A JP 2019538737 A JP2019538737 A JP 2019538737A JP 7065862 B2 JP7065862 B2 JP 7065862B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- superoxide production
- tumor
- chemiluminescence
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 127
- 201000011510 cancer Diseases 0.000 title claims description 94
- 238000012544 monitoring process Methods 0.000 title description 5
- 238000000034 method Methods 0.000 claims description 66
- 210000000440 neutrophil Anatomy 0.000 claims description 55
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims description 48
- 238000012360 testing method Methods 0.000 claims description 43
- 238000004519 manufacturing process Methods 0.000 claims description 42
- 206010027476 Metastases Diseases 0.000 claims description 24
- 239000000411 inducer Substances 0.000 claims description 19
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 claims description 14
- 230000009401 metastasis Effects 0.000 claims description 14
- 206010060862 Prostate cancer Diseases 0.000 claims description 12
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 12
- 230000004936 stimulating effect Effects 0.000 claims description 11
- 230000000638 stimulation Effects 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 4
- 238000009534 blood test Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 44
- 230000006870 function Effects 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 210000000265 leukocyte Anatomy 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 7
- 238000013517 stratification Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 206010061818 Disease progression Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000005750 disease progression Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000004235 neutropenia Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 101710091342 Chemotactic peptide Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 229920000392 Zymosan Polymers 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 2
- 230000010485 coping Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000019254 respiratory burst Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- 241001512722 Ecklonia cava Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003667 anti-reflective effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physiology (AREA)
- Ecology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1616640.7A GB201616640D0 (en) | 2016-09-30 | 2016-09-30 | Monitoring cancer recurrence and progression |
| GB1616640.7 | 2016-09-30 | ||
| PCT/GB2017/052947 WO2018060741A1 (en) | 2016-09-30 | 2017-10-02 | Monitoring cancer recurrence and progression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529959A JP2019529959A (ja) | 2019-10-17 |
| JP2019529959A5 JP2019529959A5 (enExample) | 2020-11-12 |
| JP7065862B2 true JP7065862B2 (ja) | 2022-05-12 |
Family
ID=57570942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538737A Active JP7065862B2 (ja) | 2016-09-30 | 2017-10-02 | 癌の再発および進行のモニタリング |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11435341B2 (enExample) |
| EP (1) | EP3519813B1 (enExample) |
| JP (1) | JP7065862B2 (enExample) |
| CN (1) | CN109791141B (enExample) |
| DK (1) | DK3519813T3 (enExample) |
| ES (1) | ES2881810T3 (enExample) |
| GB (1) | GB201616640D0 (enExample) |
| WO (1) | WO2018060741A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021015445A (es) * | 2019-06-27 | 2022-04-06 | Binary Llc | Ensayo de quimioluminiscencia a base de oxidasa de leucocitos fagocitica en sangre entera y en fluidos corporales aplicables a las pruebas de diagnostico de punto de cuidado (poc) la medicion de punto de cuidado (poc) de la funcion neutrofila absoluta (anf). |
| WO2022136850A1 (en) * | 2020-12-22 | 2022-06-30 | Seroxo Limited | Method for diagnosing and monitoring sepsis |
| GB2619197A (en) * | 2021-02-02 | 2023-11-29 | Seroxo Ltd | Monitoring COVID-19 progression and treatment |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006505263A (ja) | 2002-11-06 | 2006-02-16 | アイシス イノヴェイション リミテッド | ストレス曝露の定量 |
| JP2008514925A (ja) | 2004-09-23 | 2008-05-08 | バスジーン セラピューティクス， インコーポレイテッド | 腫瘍を検出し且つ治療するための組成物及び方法 |
| US20130072844A1 (en) | 2010-01-15 | 2013-03-21 | Memorial Sloan-Kettering Cancer Center | Use of entrained neutrophils to treat metastatic and micrometastatic disease in at risk patients |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159683A (en) | 1997-12-16 | 2000-12-12 | Spectral Diagnostics, Inc. | Method of determining stage of sepsis |
| WO2002099085A2 (en) * | 2001-03-27 | 2002-12-12 | Human Genome Sciences, Inc. | Human secreted proteins |
| AT504232A1 (de) * | 2006-10-03 | 2008-04-15 | Hans Dr Loibner | Prognostische parameter |
| WO2008074131A1 (en) * | 2006-12-20 | 2008-06-26 | Mcmaster University | Skin and salivary tests for the detection of sensitivity to oxidative stress based therapies |
| CN107085108A (zh) * | 2008-09-05 | 2017-08-22 | A&G药品公司 | 诊断癌症和确定癌症患者的总体生存和无病生存的方法 |
| US20140127179A1 (en) * | 2012-11-02 | 2014-05-08 | Scientific Formulations, Llc | Natural Killer Cell Formulations |
-
2016
- 2016-09-30 GB GBGB1616640.7A patent/GB201616640D0/en not_active Ceased
-
2017
- 2017-10-02 ES ES17784992T patent/ES2881810T3/es active Active
- 2017-10-02 EP EP17784992.4A patent/EP3519813B1/en active Active
- 2017-10-02 WO PCT/GB2017/052947 patent/WO2018060741A1/en not_active Ceased
- 2017-10-02 CN CN201780060988.2A patent/CN109791141B/zh active Active
- 2017-10-02 DK DK17784992.4T patent/DK3519813T3/da active
- 2017-10-02 US US16/337,035 patent/US11435341B2/en active Active
- 2017-10-02 JP JP2019538737A patent/JP7065862B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006505263A (ja) | 2002-11-06 | 2006-02-16 | アイシス イノヴェイション リミテッド | ストレス曝露の定量 |
| JP2008514925A (ja) | 2004-09-23 | 2008-05-08 | バスジーン セラピューティクス， インコーポレイテッド | 腫瘍を検出し且つ治療するための組成物及び方法 |
| US20130072844A1 (en) | 2010-01-15 | 2013-03-21 | Memorial Sloan-Kettering Cancer Center | Use of entrained neutrophils to treat metastatic and micrometastatic disease in at risk patients |
Non-Patent Citations (6)
| Title |
|---|
| Agneta Trulson, M.L.T., Sten Nilsson, M.D., Per Venge, M.D.，Lucigenin-Enhanced Chemiluminescence in Blood is Increased in Cancer，American Journal of Clinical Pathology，1989年04月01日，Volume 91, Issue 4，441-445 |
| Lejeune, M., Ferster, A., Cantinieaux, B. and Sariban, E.，Prolonged but reversible neutrophil dysfunctions differentially sensitive to granulocyte colony-stimulating factor in children with acute lymphoblastic leukaemia，British Journal of Haematology，2008年10月09日，Volume 102, Issue 5，1284-1291 |
| Morana Zivkovic, Marija Poljak-Blazi, Kamelija Zarkovic, Danijela Mihaljevic, Rudolf Joerg Schaur, Neven Zarkovic，Oxidative burst of neutrophils against melanoma B16-F10，Cancer Letters，2007年02月08日，Volume 246, Issues 1-2，100-108 |
| Schepetkin, I.A., Cherdyntseva, N.V., Borunov, E.V. et al，Decreased luminol-dependent chemiluminescence response of neutrophils to recombinant human tumour necrosis factor in patients with gastric cancer，Journal of Cancer Research and Clinical Oncology，1991年，117，172-174 |
| Shkapova, E A; Kurtasova, L M; Savchenko, A A，Lucigenin- and Luminol-Dependent Chemiluminescence of Blood Neutrophils in Patients with Renal Cancer，Bulletin of Experimental Biology and Medicine，2010年08月，149, 2，239-241 |
| W. Kaffenberger, B.P.E. Clasen, D. van Beuningen，The respiratory burst of neutrophils, a prognostic parameter in head and neck cancer?，Clinical Immunology and Immunopathology，1992年07月，Volume 64, Issue 1,，57-62 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200033327A1 (en) | 2020-01-30 |
| JP2019529959A (ja) | 2019-10-17 |
| CN109791141B (zh) | 2023-08-15 |
| EP3519813B1 (en) | 2021-06-30 |
| WO2018060741A1 (en) | 2018-04-05 |
| GB201616640D0 (en) | 2016-11-16 |
| US11435341B2 (en) | 2022-09-06 |
| EP3519813A1 (en) | 2019-08-07 |
| CN109791141A (zh) | 2019-05-21 |
| ES2881810T3 (es) | 2021-11-30 |
| DK3519813T3 (da) | 2021-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7288283B2 (ja) | 小児がん検査用尿中代謝物マーカー | |
| US20140220006A1 (en) | Lung cancer biomarkers | |
| WO2017213246A1 (ja) | 尿中代謝物による疾病診断法 | |
| JP7065862B2 (ja) | 癌の再発および進行のモニタリング | |
| Yasuda et al. | Laboratory blood data have a significant impact on tumor response and outcome in preoperative chemoradiotherapy for advanced rectal cancer | |
| van Linde et al. | Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma | |
| Wang et al. | A higher number of circulating tumor cells (CTC) in peripheral blood indicates poor prognosis in prostate cancer patients--a meta-analysis | |
| RU2670768C9 (ru) | Биологический маркер опухоли | |
| He et al. | Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA | |
| JP2019529959A5 (enExample) | ||
| US9811635B2 (en) | Immune and oxygen system measuring and drug screening method and apparatus | |
| JP7226732B2 (ja) | 尿中腫瘍マーカーによるがん検出方法、キット及び装置 | |
| CA2894660C (en) | Method and apparatus for detecting cancer in mammals | |
| ES3040729T3 (en) | Method for diagnosing and monitoring sepsis | |
| Minns et al. | DIPG-45. Radiation induces a robust interferon response in Diffuse Midline Glioma (DMG), improving the potential for combination immunotherapy | |
| Güven et al. | Evaluation of the Clinical Findings of the Patients Receiving the Diagnosis and Treatment of Covid-19 and the Data Based on the Applied Pain Scores | |
| Nidadavolu et al. | Cardiovascular-derived Circulating Cell-Free DNA Fragments are Associated with Frailty and Increased Cardiovascular Events in Older Adults | |
| Neuberger et al. | Assessing the exercise‐related kinetics of circulating cell‐free DNA, circulating tumour DNA, DNase I activity and cytokines in patients with solid tumours: A pilot study | |
| Liu et al. | Prognostic Value of Serum Lambda Free Light Chains in Nasopharyngeal Carcinoma | |
| Jiang et al. | Bone marrow-based highly sensitive proteomics profiling reveals valuable biomarkers for pediatric B-cell acute lymphoblastic leukemia | |
| WO2023233945A1 (ja) | 胆道がん検査方法 | |
| Liu et al. | Changes in L‐phenylalanine concentration reflect and predict response to anti‐PD‐1 treatment combined with chemotherapy in patients with non‐small cell lung cancer | |
| Semonche et al. | Exosomal MicroRNA in Peripheral Serum as a Noninvasive Diagnostic Biomarker for Glioblastoma | |
| Okunieff et al. | Clinical testing of the novel predictive biomarker for monitoring adverse reactions to radiation therapy | |
| CN114740196A (zh) | 标志物及其在制备评价机体免疫功能的产品中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200930 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200930 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201002 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20210324 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210324 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210706 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210827 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211004 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220311 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220405 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220426 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7065862 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |